Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Carcinoma, Renal Cell 29Carcinoma, Hepatocellular 16Prostatic Neoplasms 12Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Sarcoma 7Osteosarcoma 6Neuroendocrine Tumors 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Sarcoma, Ewing 4Melanoma 4Lung Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2

Interventions

Ipilimumab 10pembrolizumab 7Nivolumab 7incomplete Freund's adjuvant 6Temozolomide 5Dacarbazine 5tebentafusp 4Sunitinib 4MART-1 Antigen 4Carboplatin 4CTLA-4 Antigen 4sargramostim 3montanide ISA 51 3aflibercept 3Paclitaxel 3Bevacizumab 3trametinib 2relatlimab 2olaparib 2lenvatinib 2cediranib 2Vorinostat 2Thalidomide 2Taxes 2Sorafenib 2Radiosurgery 2MAGEA3 protein, human 2Lenalidomide 2Interleukin-2 2Interleukin-12 Subunit p35 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Uveal Melanoma × cabozantinib × Clear all
NCT01835145 2022-08-04

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 12 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡